On October 15, nine blockchain organizations formed the Quantum Alliance to establish open standards for evaluating post-quantum readiness in blockchains, wallets, and related infrastructure. This initiative aims to prepare blockchain technology for future quantum computing threats by ensuring systems can resist quantum attacks. The alliance's work is crucial for maintaining blockchain security as quantum computers advance. Moving forward, the group will develop and promote these standards across the blockchain industry.
The proposed Zcash wallet fix and the formation of the Quantum Alliance come as a backdrop to a mixed cryptocurrency market. For readers following the broader crypto sector, here is Pluang's market snapshot as of Oct 19, 2026 19:21 WIB: out of 50 major cryptocurrencies, 23 rose and 25 fell. Notable movers include FIL at Rp18.576 with a 2.65% decline and a buy order activity of 61%, UNI at Rp132.893 up 2.26% with 86% sell orders, and ZIL at Rp40 down 2.20% with 70% buy orders and a typical hold time of 133 days on Pluang.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
